CTOs on the Move

Tanabe Research Laboratories U.S.A.

www.trlusa.com

 
Tanabe Research Laboratories U.S.A., Inc. (TRL), is a wholly owned subsidiary of Tanabe Seiyaku Co., Ltd., headquartered in Osaka, Japan. The Research staff of TRL are highly skilled in biology and/or chemistry and at working in a collaborative
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.trlusa.com
  • 4540 Towne Centre Ct
    San Diego, CA USA 92121
  • Phone: 858.622.7000

Executives

Name Title Contact Details

Similar Companies

Auxillium East

Auxillium East is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.

Capstone Development Services,

Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...

US Micron

US Micron is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.